

ATSDR with monthly reports on their outreach efforts in support of the Registry. In addition to identifying cases through Registry enrollment, ATSDR currently identifies additional cases from three large national administrative databases (Medicare, Veterans Health Administration, and Veterans Benefits Administration). ATSDR aims to achieve more complete ALS case ascertainment by adding new data sources, including state ALS registries and non-profit ALS organizations.

Since the last continuation, there have been only minor updates to documents. All changes have been approved by the organization's IRB. These changes have no impact on the burden hours. This is a Revision request for PRA clearance. The revisions requested are designed to strengthen the usefulness of the National ALS Registry for researchers. The revisions include:

1. Updating the Consent Form to include the addition of an interagency data exchange between Unite Genomics

and the National ALS Registry. Participants will have the opportunity to share personal information relating to their health history with ATSDR through an integration between the Registry portal and a third-party online platform called Unite Genomics. This update will not impact burden hours.

2. As required by the E.O. in February 2025, all use of the term "gender" has been replaced with "sex." All changes made are minor changes to terminology as the current protocol only collects data on the registrant's sex (male/female). Changes have been made throughout the documents.

3. The OMB package being submitted reflects changes recently approved by IRB to the ALS Biorepository pre-mortem patient consent forms for the biospecimen and saliva collection. The changes include the addition of the language describing genomic data sharing and associated risk, clarification on the limited use of established cell line for commercial gain, and absence of

cell line establishment for commercial gain. Furthermore, update has been made for the ALS research application forms in Part B to include a biospecimen sample and aliquot sizes that were not previously listed, in Part C to add a postmortem sample and price that was not previously listed, and to include a new form Part E which is only applicable to the researchers making changes to their formerly approved application such as their affiliation status or additional sample request for the same study.

CDC requests OMB approval for an estimated 1,757 annual burden hours. There are no costs to the respondents other than their time. Participation in this information collection is completely voluntary for persons with ALS and for researchers. ALS service organizations report their outreach information under contract with ATSDR.

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents	Form name	Number of respondents	Number of responses per respondent	Average burden per response (in hours)
Persons with ALS .....	ALS Case Validation Questions .....	1,670	1	2/60
	ALS Case Registration Form .....	1,500	1	10/60
	Essential Questionnaire .....	750	1	6/60
	Disease Progression Survey .....	750	3	5/60
	Follow-up Questions—Demography .....	750	1	2/60
	Follow-up Questions—Lifestyle Information .....	750	1	32/60
	Follow-up Questions—Environmental Factors .....	750	1	23/60
	Follow-up Questions—ALS-associated and Clinical Factors.	750	1	7/60
	ALS Biorepository Specimen Processing Form and In-Home Collection.	325	1	30/60
	ALS Biorepository Saliva Collection .....	350	1	10/60
Researchers .....	ALS Registry Research Application Form .....	36	1	30/60
	Annual Update .....	24	1	15/60
ALS Service Organizations .....	Chapter/District Outreach Reporting Form .....	135	12	5/60
	National Office Outreach Reporting Form .....	2	12	20/60

**Jeffrey M. Zirger,**  
*Lead, Information Collection Review Office,  
 Office of Public Health Ethics and  
 Regulations, Office of Science, Centers for  
 Disease Control and Prevention.*  
 [FR Doc. 2026-08666 Filed 5-4-26; 8:45 am]  
**BILLING CODE 4163-18-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

[Docket No. ATSDR-2026-0034]

**Agency for Toxic Substances and Disease Registry; Availability of Draft Toxicological Profile for Xylene**

**AGENCY:** Agency for Toxic Substances and Disease Registry (ATSDR),

Department of Health and Human Services (HHS).  
**ACTION:** Notice with comment period.

**SUMMARY:** The Agency for Toxic Substances and Disease Registry (ATSDR), within the Department of Health and Human Services (HHS), announces the opening of a docket to obtain comments on a draft of the updated Toxicological Profile for Xylene. This action is necessary as this is an opportunity for members of the public and organizations to submit comments on drafts of the profiles. The intended effect of this action is to ensure that the public can note any pertinent additional information or reports on studies about the health

effects caused by exposure to the substances covered in the profile for review.

**DATES:** Written comments must be received on or before August 3, 2026.

**ADDRESSES:** You may submit comments, identified by Docket No. ATSDR-2026-0034 by either of the methods listed below. Do not submit comments by email. ATSDR does not accept comments by email.

- *Federal eRulemaking Portal:* <http://www.regulations.gov>. Follow the instructions for submitting comments.
- *Mail:* Agency for Toxic Substances and Disease Registry, Office of Innovation and Analytics, 4770 Buford Highway, Mail Stop S106-5, Atlanta,

GA 30341–3717. Attn: Docket No. ATSDR–2026–0034.

*Instructions:* All submissions received must include the agency name and Docket Number. All relevant comments received will be posted without change to <http://www.regulations.gov>, including any personal information provided. For access to the docket to read background documents or comments received, go to <http://www.regulations.gov>.

**FOR FURTHER INFORMATION CONTACT:** Farhana Rahman, Agency for Toxic Substances and Disease Registry, Office of Innovation and Analytics, 4770 Buford Highway, Mail Stop S106–5, Atlanta, GA 30341–3717; Email: [ATSDRToxProfileFRNs@cdc.gov](mailto:ATSDRToxProfileFRNs@cdc.gov); Phone: 1–800–232–4636.

**SUPPLEMENTARY INFORMATION:** ATSDR has prepared a draft of the updated Toxicological Profile for Xylene based on current understanding of the health effects and availability of new studies and other information since its initial release. All toxicological profiles issued as “Drafts for Public Comment” represent the result of ATSDR’s evidence-based evaluations of the available literature to provide important toxicological information on priority hazardous substances to the public and health professionals. ATSDR considers key studies for these substances during the profile development process, using a systematic review approach. To that end, ATSDR is seeking public comments and additional information or reports on studies about the health effects of these substances for review and potential inclusion in the profile. ATSDR will evaluate the quality and relevance of such data or studies for possible inclusion in the profile.

### Legislative Background

The Superfund Amendments and Reauthorization Act of 1986 (SARA) (42 U.S.C. 9601 *et seq.*) amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund) (42 U.S.C. 9601 *et seq.*) by establishing certain requirements for ATSDR and the U.S. Environmental Protection Agency (EPA) regarding the hazardous substances most commonly found at facilities on the CERCLA National Priorities List. Among these statutory requirements is a mandate for the Administrator of ATSDR to prepare toxicological profiles for each substance included on the priority list of hazardous substances (also called the Substance Priority List (SPL)). This list identifies 275 hazardous substances that ATSDR has determined pose the most significant potential threat to human

health. The SPL is available online at <https://www.atsdr.cdc.gov/programs/substance-priority-list.html>. ATSDR is also mandated to revise and publish updated toxicological profiles, as necessary, to reflect updated health effects and other information.

In addition, CERCLA provides ATSDR with the authority to prepare toxicological profiles for substances not found on the SPL. CERCLA authorizes ATSDR to establish and maintain an inventory of literature, research, and studies on the health effects of toxic substances (CERCLA section 104(i)(1)(B); 42 U.S.C. 9604(i)(1)(B)); to respond to requests for health consultations (CERCLA section 104(i)(4); 42 U.S.C. 9604(i)(4)); and to support the site-specific response actions conducted by the agency (CERCLA section 104(i)(6); 42 U.S.C. 9604(i)(6)).

### Availability

The draft toxicological profile is available online at <http://www.regulations.gov>, Docket No. ATSDR–2026–0034 and at <https://www.atsdr.cdc.gov/toxicological-profiles/about/index.html>.

### Public Participation

Interested people or organizations are invited to participate by submitting written views, recommendations, and data. Please note that comments received, including attachments and other supporting materials, are part of the public record and are subject to public disclosure. Comments will be posted on <https://www.regulations.gov>. Therefore, do not include any information in your comment or supporting materials that you consider confidential or inappropriate for public disclosure. If you include your name, contact information, or other information that identifies you in the body of your comments, that information will be on public display. ATSDR will review all submissions and may choose to redact, or withhold, submissions containing private or proprietary information such as Social Security numbers, medical information, inappropriate language, or duplicate/near duplicate examples of a mass-mail campaign. If you submit comments with reference to studies that are not publicly available such as unpublished research, those studies must be attached with your comment for review. Otherwise ATSDR may be unable to respond to portions of your comment referring to any material that is not publicly available. Do not submit comments by

email. ATSDR does not accept comments by email.

**Donata Green,**

*Associate Director, Office of Policy, Planning and Partnerships, Agency for Toxic Substances and Disease Registry.*

[FR Doc. 2026–08697 Filed 5–4–26; 8:45 am]

**BILLING CODE 4163–70–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

[30Day–26–1215]

### Agency Forms Undergoing Paperwork Reduction Act Review

In accordance with the Paperwork Reduction Act of 1995, the Centers for Disease Control and Prevention (CDC) has submitted the information collection request titled “Awardee Lead Profile Assessment (ALPA)” to the Office of Management and Budget (OMB) for review and approval. CDC previously published a “Proposed Data Collection Submitted for Public Comment and Recommendations” notice on January 13, 2026 to obtain comments from the public and affected agencies. CDC did not receive comments related to the previous notice. This notice serves to allow an additional 30 days for public and affected agency comments.

CDC will accept all comments for this proposed information collection project. The Office of Management and Budget is particularly interested in comments that:

(a) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

(b) Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;

(c) Enhance the quality, utility, and clarity of the information to be collected;

(d) Minimize the burden of the collection of information on those who are to respond, including, through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, *e.g.*, permitting electronic submission of responses; and

(e) Assess information collection costs.